Skip to main content
OpenTrials
Completed

NCT Number: NCT07457684

Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin

The goal of this retrospective study is to compare the effectiveness and cost-effectiveness of two mixed ovarian stimulation protocols in women undergoing in vitro fertilization (IVF).

The main questions it aims to answer are:

* Does the combination of follitropin delta + HP-hMG result in a higher number of utilizable blastocysts per treatment cycle compared to follitropin alfa + HP-hMG? * Does the follitropin delta based mixed protocol reduce total gonadotropin dose and cost per usable blastocyst while maintaining or improving pregnancy outcomes?

Researchers will compare follitropin alfa (Gonal-F®) + HP-hMG (Menopur®) with follitropin delta (Rekovelle®) + HP-hMG (Menopur®) to determine which protocol improves ovarian response, embryology outcomes, pregnancy rates, and overall treatment cost-efficiency.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

IVF Outcomes OVARIAN STIMULATION

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Clinique ovo

Montreal, Quebec, H4P 2S4, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women between 18-45 years included
  • First ovarian stimulation cycle only
  • Patients who used mixed protocols combining menotropin and follitropin alfa or delta
  • Patients whose Rekovelle doses were prescribed using the algorithm based on AMH and weight.

Exclusion criteria

  • Patients who did not follow the algorithm to determine follitropin delta dosing and who required dose adjustments during the stimulation
  • Patients who took concomitant treatment, such as corticosteroids, low molecular weight heparin, nonsteroidal anti-inflammatory drugs, recombinant LH or intra-vaginal vasodilators
  • Oocytes donation or fertility preservation cycles

Treatment and study plan

Primary outcomes

  1. Number of utilizable blastocysts per treatment cycle

    Time frame: For IVF performed from January 2018 to December 2024

Secondary outcomes

  1. Number of stimulation days

    Time frame: For IVF performed from January 2018 to December 2024

  2. Totals doses of rFSH, HP-hMG, and FSH

    Time frame: For IVF performed from January 2018 to December 2024

  3. Costs of rFSH, HP-hMG, and FSH

    Time frame: For IVF performed from January 2018 to December 2024

  4. Number of retrieved oocytes

    Time frame: For IVF performed from January 2018 to December 2024

  5. Number of mature oocytes (MII)

    Time frame: For IVF performed from January 2018 to December 2024

  6. Number of fertilized oocytes (2PN)

    Time frame: For IVF performed from January 2018 to December 2024

  7. Total FSH/ usable blastocysts ratio

    Time frame: For IVF performed from January 2018 to December 2024

  8. Pregnancy rates

    Time frame: For IVF performed from January 2018 to December 2024

  9. Cost per blastocyst

    Time frame: For IVF performed from January 2018 to December 2024

Sponsors and collaborators

Lead sponsor

Clinique Ovo

Industry

Registry information

Official study title

Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin (the BONANZA Study)

Acronym: BONANZA

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 9, 2026
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.